Omics-based biomarkers for diagnosis and prediction of kidney allograft rejection.

ABSTRACT: Kidney transplantation is the preferred treatment for patients with end-stage kidney disease, because it prolongs survival and improves quality of life. Allograft biopsy is the gold standard for diagnosing allograft rejection. However, it is invasive and reactive, and continuous monitoring is unrealistic. Various biomarkers for diagnosing allograft rejection have been developed over the last two decades based on omics technologies to overcome these limitations. Omics technologies are based on a holistic view of the molecules that constitute an individual. They include genomics, transcriptomics, proteomics, and metabolomics. The omics approach has dramatically accelerated biomarker discovery and enhanced our understanding of multifactorial biological processes in the field of transplantatio

SUBMITTER: Lim JH 

PROVIDER: S-EPMC9082440 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature